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Abstract The abnormal cytoskeletal organization observed in 
Alzheimer's disease has been suggested to arise from hyper- 
pbosphorylation of tau and the resultant elimination of its ability 
to associate with microtubules. This possibility has been sup- 
ported by a number of studies under cell-free conditions utilizing 
various kinases, phosphatases and their corresponding inhibitors 
each, and by treatment of intact cells with kinase and phosphatase 
activators and inhibitors. However, in studies utilizing intact cells, 
it remained difficult to attribute mierotubule compromise specifi- 
cally to tau hyperphosphorylation due to potential influence of 
inhibitors on tubuliu and/or other microtubule-associated pro- 
teins, which themselves possess assembly-regulatory phosphor- 
ylation sites. To address this difficulty, we subjected SH-SY-SY 
human neuroblastoma cells to treatment with the phosphatase 
inhibitor okadaic acid (OA), which has been previously demon- 
strated to depolymerize microtubules in these cells. OA induced 
an increase in tau hyperphosphorylation as evidenced by an in- 
crease in Alz-50 immunoreactivity and a corresponding decrease 
in Tau-1 immunoreactivity. When tau-enriched fractions from 
OA-treated cells were incubated under microtubule assembly- 
promoting conditions with twice-cycled, tau-free preparations of 
bovine brain tubulin not exposed to OA, Alz-50-immuuoreactive 
tau isoforms displayed a marked (49%) reduction in ability to 
co-assemble with bovine micrutubules as compared with Tau-1- 
and 5E2-immunoreactive isoforms. These data indicate that hy- 
perphosphorylated tau has a reduced capacity to associate with 
microtubules, and support the hypothesis that tau hyper- 
phosphorylation may underlie microtubule breakdown in Alz- 
beimer's disease. 
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1. Introduction 
Essential to the development ofany treatment to halt or slow 
the widespread degeneration f neurons that accompanies Alz- 
heimer's disease (AD) is to determine the progression of events, 
and in particular, the earliest such detectable events, that high- 
light 'at-risk' neurons in this disorder. A major pathological 
feature of affected neurons in AD is the presence of neurofibril- 
lary tangles that are comprised in large part of hyper- 
phosphorylated forms of the microtubule-associated protein 
tau (for review, see ref. [1]). 
Several converging lines of evidence point towards tau hav- 
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ing a pivotal role in AD neurofibrillary pathology. A marked 
increase in total tau content is observed in AD brains, and this 
increase is apparently due to the accumulation of abnormally 
phosphorylated forms [2]. Paired helical filaments (PHF) that 
accumulate in affected neurons in Alzheimer's disease are com- 
prised of hyperphosphorylated tau that exhibits electrophoretic 
and antigenic properties distinct from that of normal adult 
CNS tau (for reviews, see refs. [3-5]). While most or all of these 
individual phosphorylation sites are also readily detectable dur- 
ing development and are detectable in rapidly-processed biopsy 
material from normal adult brain, these sites are apparently 
phosphorylated at a higher stochiometric ratio in AD brains 
(for review, see ref. [6]). PHF-tau exhibits a decreased MT 
binding ability [7], and dephosphorylation dissociates PHFs 
and restores MT-assembly promoting properties to tau [8-11]. 
It remains impossible, however, to confirm at present 
whether in AD tau is first hyperphosphorylated, which induces 
its dissociation from MTs, leading in turn to their collapse, or 
whether MT collapse represents an initiating phenomenon, and 
newly-dissociated tau subsequently becomes hyperphosphor- 
ylated. Consistent with the former possibility is that phosphor- 
ylation of tau at critical MT-binding site(s) prevents proper 
association of tau with MTs [12-20] and may therefore subject 
tau to AD-like hyperphosphorylation. That tubulin from AD 
brains remains assembly-competent is also consistent with the 
former possibility [8]. By contrast, however, the observation of 
rapid tau hyperphosphorylation f llowing colchicine- induced 
MT collapse in the present and in a previous tudy [21] suggests 
that the latter possibility (i.e. initial MT collapse) could at least 
partially underlie tau hyperphosphorylation n AD. An addi- 
tional, plausible hypothesis for the development of these mor- 
phological aspects accompanying AD neuropathology is that 
both phenomena contribute to the full extent of tau hyper- 
phosphorylation a d collapse of the MT system as follows: (1) 
some phosphorylation f tau at MT-binding sites, perhaps as 
a consequence of kinase hperactivation during ongoing cycles 
oftau association~tissociation with MTs, effectively withdraws 
tau molecules from the binding-competent tau pool; (2) a lim- 
ited degree of MT destabilization e sues, resulting in additional 
tau liberation; (3) this newly-dissociated tau is blocked by site- 
specific phosphorylation from further MT association; (4) addi- 
tional rounds of these phenomena lead to collapse of the MT 
system; (5) binding-incompetent tauwould be subjected to pro- 
gressive AD-like hyperphosphorylation. In this regard, a recent 
examination of MT-promoting activities of tau from AD and 
control brains suggested that hyperphosphorylated, binding- 
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incompetent tau may further exacerbate MT breakdown by 
scavenging normal  tau [22]. 
A number  of kinases have been reported to induce normal 
tau to exhibit PHF-l ike characteristics [23-37]. In addit ion to 
the potential involvement of altered kinase activities in AD 
neuropathology, protein phosphatase activities are altered in 
AD, and have been implicated in the accumulation of hyper- 
phosphorylated tau [38]. This possibility has been substantiated 
by observation that the phosphatase inhibitor, okadaic acid 
(OA) increases phosphorylat ion-dependent,  AD-l ike tau im- 
munoreact ivity in cultured neurons and neuroblastoma [39 
41], brain slices [42] and brain in situ [43,44]. However, OA 
treatment may induce MT destabil ization by several potential 
mechanisms. These may include interference with dephos- 
phorylat ion of both tubulin and tau, since both the ability of 
~-tubul in to assemble into MTs and the ability of tau to pro- 
mote MT assembly and stabilize MTs are inhibited by site- 
specific phosphorylat ion [12-20]. Whether or not OA-induced 
phosphorylat ion events actually dissociate tau from MTs, lead- 
ing to global MT disassembly, or whether tau can undergo 
assembly-restrictive OA-induced phosphorylat ion only follow- 
ing dissociation from MTs during normal association-dissocia- 
tion cycles is not clear. That  increased tau phosphorylat ion 
accompanies colchicine-induced MT disassembly as seen herein 
and in a previous tudy [18] is consistent with the latter possibil- 
ity. In the latter case, cont inued 'scavenging' of tau by OA- 
induced phosphorylat ion may eventually be expected to desta- 
bilize MTs to the point of collapse of the MT network. More- 
over, the relative contr ibution, if any, of OA- induced tubulin 
hyperphosphorylat ion to inhibit ion of MT assembly remains 
unclear. While the present analyses cannot  differentiate among 
these possibilities, however, the addit ional observation of lyso- 
somal accumulat ion following MT destabil ization by OA sup- 
ports the previous hypothesis [8,9,19], that disruptions in the 
MT system may represent a critical early event leading to AD 
neuropathology. Moreover, OA-induced interference with nor- 
mal phosphorylat ion of other MAPs  [39] and/or other cytoskel- 
etal protein such as neurofi laments [45] could contr ibute to MT 
destabil ization, since MAP-mediated interactions between 
MTs and neurofi laments mediate axonal stabil ization [46]. 
In initial efforts to address these issues, we examined whether 
or not OA-treatment of human neuroblastoma cells reduced 
the capacity of various tau isoforms to associate with ex- 
ogenous, non-OA-treated MTs. 
2. Materials and methods 
2.1. Cell eulture and treatment 
SH-SY-5Y cells (originally obtained from the stocks of Dr. June L. 
Biedler, Memorial Sloan-Kettering Cancer Center, Rye, New York) 
were cultured in Dulbecco's modified Eagle's medium containing 10% 
fetal calf serum (FCS) at 37°C in a humidified atmosphere containing 
10% CO 2 . Twenty-four hours later, the medium was replaced with 
medium containing 1/IM okadaic acid (OA) for 48 h. All reagents and 
chemicals were obtained from Sigma Chem. Co. (St. Louis, MO). 
2.2. Immunocytochemistry 
Treated cultures and untreated controls were rinsed in Tris-buffered 
saline (TBS; pH 7.4), fixed with 4% paraformaldehyde in 0.1 M phos- 
phate buffer for 15 min at room temperature, and rinsed 3x in TBS. 
Immunocytochemistry was carried out on fixed cultures using I : 100 
dilutions of monoclonal antibody Alz-50 (raised against a neurofibril- 
lary tangle preparation from AD brains [47,48] or monoclonal ntibody 
Tau-1 (which reacts only with tau that has not been phosphorylated at 
a site that is hyperphosphorylated in AD; obtained from Boehringer- 
Mannheim, Indianapolis, IN) [49] followed by incubation with the 
appropriate peroxidase- (Sigma) or alkaline phosphatase-conjugated 
(Boehringer-Mannheim) secondary antibody and visualization by 
standard methodologies a described previously [50]. 
2.3. Enrichment of tau from SH-SY-5 Y lysates 
Cells were scraped from the plate and homogenized (50 strokes in a 
glass-Teflon homogenizer) in 1% Triton X-100 in 50 mM Tris-HC1 (pH 
7.4). Tau-enriched fractions were prepared as described [51]: The Tri- 
ton-soluble fraction was heated at 95°C for 15 min then the above 
centrifugation was repeated; the resulting supernatant, containing heat- 
stable, Triton-soluble proteins, contained virtually all of the tau as 
confirmed by immunoblot analyses (e.g. Fig. 2). 
2.4. Isohttion of bovine brain tubulin 
Bovine brain was homogenized in PEM buffer (100 mM PIPES (pH 
6.6) containing 1mM EGTA and 1 mM MgC12) at 4°C and centrifuged 
at 40,000 x g for 30 min. GTP was added to the resulting supernatant 
at final concentration f 1 mM and the supernatant was incubated for 
30 min at 37°C to promote MT assembly, followed by centrifugation 
at 40,000 x g for 30 rain. The crude MT pellet was resuspended in PEM 
buffer at 4°C and this latter suspension and assembly procedure was 
repeated for a total of 3 cycles. The final pellet of purifed MTs was 
resuspended in 1/10 volume of PEM buffer and stored at -80°C. For 
dissociation of bovine MAPs from MTs, this preparation was made 0.7 
M NaC1 in PEM, and centrifuged, first at 40,000 x g at 4°C (to sedi- 
ment any denatured tubulin-containing a gregates) and the resulting 
supernatant a 40,000 x g for 30 min at 37°C; the MAP-free MT pellet 
was utilized for further analyses [52]. 
2.5. MT assembly assays 
Bovine brain tubulin and heat-stable Triton-soluble fractions from 
untreated and OA-treated SH-SY-5Y cells were incubated separately 
and together in an excess of 0.1 M in PEM buffer for 30 min at 30°C 
in the presence of 10/.tM taxol (generous gift of Dr. M. Mercken, 
McLean Hospital, Belmont MA), then centrifuged at 100,000 x g for 
15 min at the respective temperature. 
2.6. Electrophoresis and immunoblot analyses 
Heat-stable Triton-soluble fractions (100/.tg of total protein) from 
OA-treated and untreated cells, bovine brain microtubules (10/zg of 
total protein), and supernatants and pellets obtained from sedimenta- 
tion analyses were electrophoresed on SDS 7% polyacrylamide g ls and 
transferred to nitrocellulose using a Hoefer Transphor apparatus as 
described [50]. The proteins were visualized by sequential reaction of 
the replica in TBS overnight at room temperature with Tau-1, Alz-50, 
monoclonal antibody 5E2 (which reacts with tau regardless of phos- 
phorylation state; generous gift of Dr. K. Kosik, Brigham and 
Women's Hospital, Boston, MA) and with a monoclonal antibody 
directed against all forms of ~-tubulin (Sigma), followed by the appro- 
Control OA 
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Fig. 1. Okadaic acid increases hyperphosphorylated auimmunoreac- 
tivity in SH-SY-5Y neuroblastoma cells. Cells were treated with 1/.tM 
okadaic acid for 0 (Control) or 48 h (OA) then processed for immunocy- 
tochemistry with Tau-I or Alz-50. Note the marked diminution of 
Tau-I immunoreactivity and corresponding increase in Alz-50 im- 
munoreactivity following OA treatment. 
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Fig. 2. Distribution of tau during fractionation of SH-SY-5Y cells. Cells 
were homogenized in the presence of 1% Triton, the Triton-insoluble 
cytoskeleton (CS) was sedimented, and the resulting Triton-soluble 
material was heated at 56°C as described in section 2, then centrifuged 
to yield a (Triton-soluble) heat-labile (HL) pellet and a heat-stable (HS) 
supernatant. Immunoblot analysis revealed the quantitative recovery 
of both Tau-I and Alz-50 immunoreactive tau isoforms in the heat- 
stable supernatant fraction. This fraction was not assembly-competent 
in the absence of exogenous tubulin, since incubation of this fraction 
at 37°C in the presence of 10BM taxol but in the absence of exogenous 
tubulin followed by high speed centrifugation did not result in sedimen- 
tation (WP) of either Tau-1 or Alz-50 immunoreactive tau isoforms. 
priate alkaline phosphatase-conjugated secondary antibody and visual- 
ized as described [50]. Immunoblots were subjected to densitometric 
analysis as described previously [53]. 
3. Results 
As has been demonstrated in other neuronal and neuroblas- 
toma culture systems [394 1], treatment of SH-SY-5Y cells with 
OA markedly reduced Tau-1 immunoreactivity and increased 
Alz-50 immunoreactivity (Fig. 1). To enrich for tau, the Triton- 
soluble fraction from OA-treated cells was subjected to heating 
at 95°C followed by centrifugation to yield a supernatant con- 
taining heat-stable proteins [51]. Immunoblot analyses of frac- 
tions derived from OA-treated (Fig. 2) and untreated control 
cells (not shown) demonstrated, as has been shown for tau 
derived from brain [51] that both Tau-1- and Alz-50-im- 
munoreactive tau isoforms were quantitatively recovered 
within the heat-stable cytosolic fraction. 
To ascertain the ability of differentially-immunoreactive tau 
isoforms from OA-treated SH-SY-5Y cells to co-assemble with 
MTs, this fraction was incubated under MT-assembly-promot- 
ing conditions with and without tubulin purified from bovine 
brain by two assembly/disassembly cycles. The assembly-com- 
petence of this tubulin preparation was first demonstrated by 
sedimentation by high-speed centrifugation following incuba- 
tion for 30 min in MT assembly buffer at 30°C in the presence 
of taxol (Fig. 3; Table 1). Immunoblot analyses confirmed the 
absence of detectable 5E2, Tau-1, Alz-50 immunoreactivity 
within the bovine brain MT preparation prior to the addition 
of the tau-enriched SH-SY-5Y fraction (Fig. 3). 
When heat-stable Triton-soluble fractions from OA-treated 
cells were co-incubated with bovine brain tubulin in an excess 
of MT assembly buffer, significantly more Tau-1-immunoreac- 
tive tau was sedimented than Alz-50-immunoreactive tau(Fig. 
4; Table 1). As was observed with the MT preparation alone 
(Fig. 3), significantly more of each tau isoform was sedimented 
when cellular fractions were co-incubated with the MT prepa- 
ration at 30°C in the presence of taxol, however, Alz-50-im- 
munoreactive isotbrms demonstrated a markedly reduced abil- 
ity to co-assemble with exogenous MTs as compared to that of 
Tau-1- or 5E2-immunoreactive soforms within the same cellu- 
lar fraction. By contrast, neither Tau-1- and Alz-50-im- 
munoreactive tau isoforms from OA-treated cells were capable 
of sedimenting when the heat-stable fraction from SH-SY-5Y 
cells was incubated in an equivalent amount of MT assembly 
buffer at 30°C in the presence of 10/2M taxol but in the absence 
of exogenous bovine brain tubulin (Fig. 2). Although the rela- 
tive amounts of Tau-1 and Alz-50-immunoreactive taudiffered 
substantially between non-OA-treated and OA-treated cells 
(Fig. 1), Tau-1 and Alz-50-immunoreactive tau isoforms en- 
riched from non-OA-treated cells exhibited identical distribu- 
tion and MT assembly behavior as those presented herein for 
OA-treated cells (not shown). 
4. Discussion 
Compromise of the MT system has been suggested to repre- 
sent an antecedent event in the development of AD neuropa- 
thology which may underlie PHF formation [9,22] and, by 
disruption of MT-dependent membrane cycling, foster the ac- 
cumulation of lysosomal hydrolases that accompany the early 
stages of neurodegeneration n AD [54,55]. It remains impossi- 
ble to confirm at present whether in AD tau is first hyper- 
phosphorylated, which induces its dissociation from MTs, lead- 
ing in turn to their collapse, or whether MT collapse represents 
an initiating phenomenon, and newly-dissociated tau subse- 
quently becomes hyperphosphorylated. Accordingly, experi- 
mental alteration in kinase and phosphatase activities in neu- 
ronal cell culture systems represent a useful approach towards 
unraveling antecedent events. In previous tudies, phosphatase 
inhibition by OA treatment has been shown to disrupt neuro- 
blastoma MTs [50,56] and increase hyperphosphorylated tau 
immunoreactivity in cultured neurons, neuroblastoma [39- 
41,57], brain slices [39] and brain in situ [40,41]. While tau that 
has been dissociated from MTs is susceptible to hyper- 
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kDa sup pel I sup pel 
i 
97 - 
68 -  
42-  
30-  
21-  
Tau-1 5E2 
sup pel sup pel 
Fig. 3. Assembly of bovine brain tubulin. Tubulin purified from bovine 
brain by two assembly/disassembly cycles was incubated for 30 min at 
4°C in the absence of taxol and at 30°C in the presence of 10,uM taxol, 
then subjected to high-speed centrifugation and separated from en- 
dogenous MAPs as described in section 2. Immunoblot analysis of 
resulting pellets and supernatants demonstrated MT assembly as evi- 
denced by sedimentation ftubulin immunoreactivity; see Table 1 for 
quantitation. Immunoblot analyses also confirmed the absence of de- 
tectable Alz-50, Tau-1 and 5E2 immunoreactivity within the bovine 
brain MT preparation prior to the addition of the tau-enriched SH-SY- 
5Y fraction. 
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Fig. 4. Alz-50-immunoreactive tau isoforms demonstrate a reduced 
ability to co-sediment with exogenous microtubules. Heat-stable Tri- 
ton-soluble fractions from OA-treated cells were co-incubated for 30 
min at 30 ° C in the presence of 10 ¢tM taxol with bovine brain tubulin 
in an excess of MT assembly buffer and subjected to high-speed centrif- 
ugation as described in section 2. Immunoblot analysis demonstrated 
that significantly more Tau-1- and 5E2-immunoreactive tauwas sedi- 
mented than Alz-50-immunoreactive taufollowing incubation with as- 
sembling MTs. 
phosphorylation, and such hyperphosphorylation will prevent 
its subsequent association with MTs [1,9,12,16], it remains un- 
clear in such studies whether OA treatment fosters MT desta- 
bilization by interference with phosphorylation/dephos- 
phorylation cycles oftau, tubulin or both, since both the ability 
of ~-tubulin to assemble into MTs and the ability of tau to 
promote MT assembly and stabilize MTs are inhibited by site- 
specific phosphorylation [12 17]. Moreover, OA-induced inter- 
ference with phosporylation/dephosphorylation cycles of other 
MAPs [39] and/or other cytoskeletal protein such as neurofil- 
aments [45] could contribute to MT destabilization, since 
MAP-mediated interactions between MTs and neurofilaments 
mediate axonal stabilization [46]. To address this issue, in the 
present study we monitored the ability of phosphorylation- 
dependent and nonphosphorylation-dependent immunoreac- 
tive tau isoforms derived from OA-treated cells to co-assemble 
with exogenous (non-OA-treated) assembly-competent MTs. 
We observed in the present study that tau isoforms display- 
Table 1 
Alz-50-positive tau has a reduced ability to co-sediment with exogenous 
microtubules 
Antigen Sample Relative % Sedimented** 
density* 
~-Tubulin Supernatant 1 
Pellet 66 99% 
Tau- 1 Supernatant 109 
Pellet 87 44% 
Alz-50 Supernatant 31 
Pellet 9 23% 
5E2 Supernatant 85 
Pellet 42 49% 
*Calculated as the staining intensity obtained following densitometric 
analysis using NIH Image software as described in section 2 of the 
appropriate band minus background of adjacent areas of replicas of 
similar density; values presented represent the average obtained tbr two 
replicas from separate xperiments for each antigen. 
**Calculated as the (average amount in the pellet/(average amount in 
the pellet + average amount in the supernatant) x 100 for each condi- 
tion. 
ing Alz-50 immunoreactivity, indicative of an altered configura- 
tion generated by hyperphosphorylation, exhibited a markedly 
reduced ability to associate with exogenous MTs than did 
isoforms displaying non-phosphorylated (Tau-1) or total (5E2) 
immunoreactivity. Despite that there may be overlap between 
the populations of tau molecules displaying the phospho-de- 
pendent ALZ-50 and Tau-1 epitopes, these antibodies appar- 
ently represent useful markers of 'hyperphosphorylated' and 
'hypophosphorylated' tau, since Alz-50-immunoreactive tau in- 
creased, and Tau-l- immunoreactive tau decreased, following 
inhibition of phosphatase activity. While these results do not 
eliminate that possibility that the MT system is comprised inde- 
pendently of effects on tau, they confirm that alteration of tau 
phosphorylation/dephosphorylation cycles within intact cells 
can render tau incompetent to associate with MTs. The findings 
of the present study are largely consistent with those of a pre- 
vious examination of the assembly-competence of tau from 
untreated SH-SY-5Y cells [58]. In the present study, cells were 
treated with OA merely to increase the levels of Alz-50-positive 
tau, which, although present, is relatively low in SH-SY-5Y cels 
in our hands in the absence of additional treatments; the (low 
levels of) Alz-50-positive tau and Tau-l-positive tau exhibited 
the identical abilities to coassemble with exogenous MTs as did 
tau isoforms enriched from OA-treated cells. 
The findings of the present study are consistent with previous 
hypotheses [9,22,58] that tau hyperphosphorylation contributes 
to the breakdown of MTs in AD. 
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